A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
Source:
cnbc
May 31, 2026 · 05:00
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.
The original article opens on the publisher's website.
More from General
View topic →Australia posts second-quarter growth of 2.1%, beating expectations
cnbc
Sep 1, 2026 · 18:47
Fake 10 Downing Street listing exposes 'unfit' Booking.com, says consumer group
bbcTechnology
Sep 1, 2026 · 18:27
Massachusetts’ 80-year-old senator sees off primary challenge over his age
financialTimes
Sep 1, 2026 · 18:06
Pentagon chaos deepens after Driscoll quits in clash with Hegseth
financialTimes
Sep 1, 2026 · 17:47
Incumbent Sen. Ed Markey wins Massachusetts' Democratic primary for US Senate
nprNews
Sep 1, 2026 · 17:38
Countries mentioned